Reason for request
Inclusion of the list of medicines reimbursed by National Insurance and approved for use by hospitals. .
Clinical Benefit
| Substantial |
The actual benefit of these drugs is substantial. |
Clinical Added Value
| minor |
INOVELON offers a minor (level IV) improvement in actual benefit in the therapeutic management of patients aged 4 and over with Lennox-Gastaut syndrome that is resistant to first-line treatments. |
eNq1mF1v2jAUhu/5FVEudkfCZ6FbQrWxdkNqNUZBm3aDTHIoZsZO/UHpfv0cAipMjtoZfJk4ec+xz/HjV46uNivirYELzGjs14Oa7wFNWIrpQ+xPxjfVrn/Vq0RLtEYHn3WCWlBv+F5CkBCxn48GM0BUBD/vbj+D/h+436t4EZstIZFH3ymJSfAVicUdyvJvvGjNcOqtQC5YGvuZktu3XiQk11n0nhj/LTKUQBTu3hyOLqetw/dRmIu9QVUJ4LeIPhhFgVppJopzoLKPJDww/lySb9NKG4sRCKZ4AkMkF0PO1jiF1BhijogAqyDzp/Qe+JqAzIMYxcNlshJW4miJNiN4HJiT/qhH+3Ijq7VqvdNpNFvddq3eaNesQvGDpTJXQU8iTKadi4tGtxUCDTFlayCMWtZmyLhExFFVsOgfN5ajOBweX61+ikVG0HOwFJntUiGO9DBwvf3dTSSfwZhrIBG9Zv/oU0VI+J9ZT3a4cJRxTqM+U1SWUONmZLsQfUYlbMoragc6udn1IgZxPtk/jJohP1QzghNbpGnoKBByMhqUE+2cMPiEBEy4Oxr8wDRlT+L8lDmsqqPssy0ojaIZT+vTxmX3ot5uW2+iX7qFSk6Ya8VZBqHmDxanYGVA5+xUoOiuNEvte/Js7bj1OSxBBEqcTtWSLboP98bMWae720XFgFH0y/XYtj2+K+DP99tHozRO431h7bjrAua6F1/Lu9i1cTZt1trdy2brHVplH/YOOrZ0y4WoE7OsuBkxCykz8T4MF0hUBdJrGcx5Of6vjNM+x9Q1a18q6c7LOzn7Cy9UcNZR6rPiAH17CW3362vO4FS3u/t/56qNMSRXcEIdCrQ7A/Dg+vxMf7G6ztIeHqHFXZitLUUSM+rKLqmZUfGkU0SXld5wzYZv8zkuuVYpbcsoLK50epUozK9zepW/NTb+DA==
UhjncZggAGPCdQ4E
